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Adiposity is an established risk factor for postmenopausal breast cancer. Recent data suggest that
high insulin levels in overweight women may play a major role in this relationship, due to
insulin’s mitogenic/anti-apoptotic activity. However, whether overweight women who are
metabolically healthy (i.e. normal insulin sensitivity) have elevated risk of breast cancer is
unknown. We investigated whether overweight women with normal insulin sensitivity (i.e.,
homeostasis model assessment of insulin resistance [HOMA-IR] index, or fasting insulin level,
within the lowest quartile [q1]) have increased breast cancer risk. Subjects were incident breast
cancer cases (N=497) and a subcohort (N=2,830) of Women’s Health Initiative (WHI) participants
with available fasting insulin and glucose levels. In multivariate Cox models, metabolically
healthy overweight women, defined using HOMA-IR, were not at elevated risk of breast cancer
compared to metabolically healthy normal weight women (hazard ratio [HR]HOMA-IR=0.96; 95%
confidence interval [CI],0.64-1.42). In contrast, the risk among women with high (q3-4) HOMAIRs was elevated whether they were overweight (HRHOMA-IR=1.76; 95% CI,1.19-2.60) or normal
weight (HRHOMA-IR=1.80; 95% CI,0.88-3.70). Similarly, using fasting insulin to define metabolic
health, metabolically unhealthy women (insulin q3-4) were at higher risk of breast cancer
regardless of whether they were normal weight (HRinsulin=2.06; 95% CI,1.01-4.22) or overweight
(HRinsulin=2.01; 95% CI,1.35-2.99), whereas metabolically healthy overweight women did not
have significantly increased risk of breast cancer (HRinsulin=0.96; 95% CI,0.64-1.42) relative to
metabolically healthy normal weight women. Metabolic health (e.g., HOMA-IR or fasting insulin)
may be more biologically relevant and more useful for breast cancer risk stratification, than
adiposity per se.
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INTRODUCTION
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Excess body weight is a well-established risk factor for breast cancer in postmenopausal
women.(1, 2) Until recently, this relationship was largely thought to be attributable to the
prevalence of higher estrogen levels in overweight women which is an established risk
factor for postmenopausal breast cancer. (3, 4) However, being overweight is also associated
with high levels of insulin, which has mitogenic and anti-apoptotic activity(5, 6) and recent
cohort data have linked insulin levels with breast cancer risk.(7, 8) A large prospective
study, for example, reported a highly significant 2.4-fold increased risk of breast cancer
among postmenopausal women with insulin levels in the highest relative to the lowest
quartile, after adjusting for multiple breast cancer risk factors, including serum estradiol.(7)
In subsequent analyses using mediation analysis methods, it was reported that the obesity –
breast cancer association is more greatly attributable to insulin than to estradiol levels.(9)
These observations lead to an important but yet untested clinical corollary to the insulin –
breast cancer association, namely, that those overweight women with high insulin levels but
not those with normal insulin levels will be at increased risk of breast cancer relative to
healthy normal weight women. Indeed, a metabolically healthy obese phenotype has been
posited to be relevant for cardiovascular disease risk, (10-12) and there is accumulating
evidence that individuals who are overweight (body mass index [BMI] ≥25 kg/M2) but who
have normal insulin sensitivity (e.g., a low quartile of homeostasis model assessment of
insulin resistance [HOMA-IR] index) have little, if any, excess risk of cardiovascular events.
(13-16) Therefore, we compared the risk of incident postmenopausal breast cancer among
metabolically healthy overweight women to that in metabolically healthy normal weight
women.
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METHODS
Study Population

Author Manuscript

The data analyzed were from two separate prospective studies of incident postmenopausal
breast cancer and fasting serum insulin and glucose levels based in the Women’s Health
Initiative (WHI), a large prospective cohort study of postmenopausal women aged 50-79
years at enrolment.(17) WHI has both an observational component (N=93,676) and a
clinical trial component (N=68,132) with three arms: hormone therapy (HT), dietary
modification, and vitamin D/calcium supplementation. All components were conducted at
the same clinical centers and shared relevant methods including a standardized blood
collection protocol. All WHI participants were aged 50-79 years at baseline and were
recruited at 40 clinical centers across the United States between October 1, 1993 and
December 31, 1998. At baseline, a physical examination that included measurement of
height and weight, and collection of fasting blood, was conducted. Incident cancer was then
ascertained through annual or semi-annual self-administered questionnaires or by selfreport, and were subsequently confirmed through centralized review of all pathology reports,
discharge and consultant summaries, operative and radiology reports, and tumor registry
abstracts.
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The first of the two WHI breast cancer studies used was a case-cohort investigation of nondiabetic women based in the observational component of WHI that included 835 incident
cases diagnosed over a mean of 8.2 years of follow-up and a randomly selected subcohort of
816 women present at the baseline visit.(7) The second study was a conventional cohort
investigation involving a random sample of approximately 1% of women in the
observational (N=1,054) and 6% in the clinical trial component (N=4,396), who were asked
to provide extra blood for serologic studies.(8) A total of 190 incident breast cancer cases in
this second study were diagnosed over 8 years of follow-up. The combined comparison
group from both studies (each of which were randomly selected subjects) is referred to,
herein, as the subcohort. As in prior reports, women who were either diabetic or currently
using hormone therapy (HT) were excluded, due to the impact of these factors on insulin
levels,(7, 18) leaving 497 cases and a subcohort of 2,830 women. All subjects included in
the current analysis had fasting insulin and glucose levels available.
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Categorization of Metabolic Health
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We compared the risk of incident postmenopausal breast cancer among metabolically
healthy normal weight women (BMI 18-24.9 kg/m2 and HOMA-IR-q1) to that in
metabolically unhealthy overweight women (BMI ≥25 kg/m2 and HOMA-IR quartiles 3 and
4 [HOMA-IR-q3+4]), metabolically healthy overweight women (BMI ≥ 25 kg/m2 and
HOMA-IR-q1), as well as metabolically unhealthy normal weight women (BMI 18-24.9
kg/m2 and HOMA-IR-q3+4) – similar to the design of prior studies of cardiovascular
disease.(14-16) HOMA-IR-q2 was excluded to make the two strata discrete (non-abutting)
categories. HOMA-IR is a standard measure of insulin resistance and is defined by a
formula that incorporates both insulin and glucose levels ([fasting insulin (IU/mL) × fasting
glucose (mg/dL)] /22.5). However, as our hypotheses focused particularly on the impact of
insulin on breast cancer risk, we also a priori used insulin quartile itself to distinguish
metabolically healthy from unhealthy women.
Statistical Analyses

Author Manuscript

Hazard ratios (HRs) and 95% confidence intervals (CI) for the association of metabolic
health subtypes with incident breast cancer were estimated using Cox proportional hazards
regression modeling that employed the Self-Prentice method for robust standard error
estimates (to account for the case-cohort design), with time from study enrollment as the
underlying time metric. (19) Statistical analyses adjusted for established breast cancer risk
factors, namely, age (50–54 [referent], 55–59, 60–64, 65–69, 70–74, or 75–79 years),
ethnicity (white [referent], black, Hispanic, or Asian/other), age at menarche (≤10, 11–
12[referent], or ≥13 years) and menopause (≤42 [referent], 43–48, 49–51, or ≥52 years),
parity (0 [referent], 1, or ≥2 live births), first degree relative with breast cancer (yes or no),
education (high school or lower [referent], college, or postgraduate education), alcohol
consumption (assessed as the number of servings per week during the preceding 3 months
(none [referent], <3, or ≥3), physical activity (assessed as metabolic equivalent tasks per
hour per week [METs; defined as the caloric need per kilogram of body weight per hour of
activity divided by the caloric need per kilogram of body weight per hour at rest] and
categorized as quartiles (<3.75, 3.75–9.82, 9.83–18.74, ≥18.75), as well as which of the two
WHI studies each subject was enrolled in (observational study or clinical trial) and, among
Cancer Res. Author manuscript; available in PMC 2016 January 15.
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those who participated in the clinical trials, which specific clinical trial arm they were
assigned to (hormone therapy [estrogen-alone, estrogen plus progestin], calcium/vitamin D
and dietary modification) and whether they were a member of the placebo or treatment
group. In addition, caloric intake, total carbohydrate, saturated fat and glycemic load and
index were also considered as potential confounding variables in the analysis but their
inclusion in the multivariable model did not meaningfully alter the regression coefficients
and were therefore not included in the final models. Individuals were censored at diagnosis
of breast cancer, death, or at the end of follow-up. Data from each of the two contributing
WHI studies of insulin, glucose and breast cancer were combined and were analyzed using a
case-cohort approach with each study permitted to retain its individual baseline hazards
function. (19) The proportionality of the data was verified by graphical inspection and by
Schoenfeld residuals. All tests of statistical significance were two sided, and P values less
than .05 were considered statistically significant. All analyses were performed using SAS
statistical software (version 9.1, Cary, NC).

Author Manuscript

RESULTS
Table 1 shows selected baseline characteristics of the cases in the analysis as well as the
non-cases in the subcohort. The two groups did not differ significantly by ethnicity, BMI or
age at menarche. However, cases (median age = 65) were on average older than non-cases in
the subcohort (median age = 63), more likely to be college educated, to be nulliparous, have
a later age at menopause, to have a first degree relative with breast cancer, and also
consumed more alcohol and engaged in more physical activity.
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In multivariate Cox proportional hazards models, metabolically unhealthy overweight was
associated with a significantly increased risk of incident breast cancer (HRHOMA-IR=1.76;
95% CI, 1.19-2.60; P=0.005) compared to metabolically healthy normal weight women
(Table 2). Further, a similar association was observed for metabolically unhealthy normal
weight though the relationship did not reach statistical significance (HRHOMA-IR=1.80; 95%
CI, 0.88-3.70; P=0.11). No relationship, however, was observed between breast cancer and
metabolically healthy overweight (HRHOMA-IR=0.96; 95% CI, 0.64-1.42; P=0.83) compared
to metabolically healthy normal weight women. In addition, the hazard ratio directly
contrasting breast cancer risk in overweight women who were metabolically unhealthy
versus healthy was HR=1.84 (95% CI, 1.38-2.45; p<0.0001).

Author Manuscript

We additionally used insulin quartile to differentiate metabolically healthy (q1) versus
unhealthy (q3+q4) women. Statistically significant associations between breast cancer risk
and metabolic health were observed, regardless of whether women were normal weight
(HRinsulin=2.06; 95% CI, 1.01-4.22; P=0.048) or overweight (HRinsulin=2.01; 95% CI,
1.35-2.99; P=0.001), whereas metabolically healthy overweight women did not have
significantly increased risk of breast cancer (HRinsulin=0.96; 95% CI, 0.64-1.42; P=0.82)
relative to metabolically healthy normal weight women. Further, the HR directly contrasting
cancer risk in overweight women who were metabolically unhealthy versus healthy (based
on insulin) was HR=2.11 (95% CI: 1.58-2.81; p<0.0001).
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CONCLUSION
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Overall, the results from this study suggest that metabolic health status (as defined by
HOMA-IR or fasting insulin levels) and not adiposity per se, may be the relevant factor
associated with risk of postmenopausal breast cancer. These findings are consistent with
recent reports that overweight individuals with normal insulin sensitivity are not at increased
risk of cardiovascular disease, and collectively provide further evidence of the existence of a
healthy obese phenotype.(10-12) Our findings also support the hypothesis that
hyperinsulinemia is a significant risk factor for breast cancer, independent of adiposity and
that insulin, or a closely-related mechanism, may be driving development of breast tumors.
Several prospective studies have now reported significant, positive associations between
fasting insulin or C-peptide (a marker of insulin secretion) (7, 8, 20-22) and there is
evidence that insulin plays a significant role in mediating the obesity-breast cancer
relationship.(7,9)
We note that our conclusions are limited by the fact that only a single insulin and glucose
measurement were available from the study participants and that multiple measurements
over time would enable a more precise assessment of long-term metabolic health. Further,
our sample size was not large enough to further stratify by breast cancer subtypes such as
those defined by estrogen receptor expression. Given potential cross-talk between estrogen
and insulin signaling, it is possible that the association of metabolic health with breast
cancer varies by breast tumor estrogen receptor subtype and future studies should be of
sufficient sample size to examine this hypothesis with adequate precision.

Author Manuscript

In conclusion, the current findings raise the possibility that HOMA-IR or fasting insulin
levels may be useful in combination with other predictors of breast cancer risk in efforts to
individualize breast cancer screening practices.
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Selected baseline characteristics of the study population
Variable§

Cases (N=497)

Subcohort (N=2,830)

P-value¶

Age (years)

65 (59 to 70)

63 (57 to 69)

<.0001

Observational Study Cohort

401 (80.7)

756 (26.7)

N/A

Clinical Trial Cohort

96 (19.3)

2074 (73.3)

White

394 (79.3)

1591 (56.4)

Black

60 (12.1)

634 (22.4)

Hispanic

22 (4.4)

340 (12.0)

Asian/other

19 (3.8)

263 (9.2)

2 (0.4)

2 (0.1)

Women’s Health Initiative, N(%)

Ethnicity, N (%)

Missing

Author Manuscript

Body mass index (BMI;

Kg/M2),

0.17

N(%)

Normal (BMI<25.0)

155 (31.2)

Overweight (25.0-<30.0)

165 (33.2)

998 (35.3)

Obese (≥30.0)

177 (35.6)

1070 (37.8)

762 (26.9)

41 (8.2)

193 (6.8)

11-12

203 (40.8)

1101 (38.9)

13+

250 (50.3)

1523 (53.8)

3 (0.7)

13 (0.5)

Age at Menarche, N (%)

0.44

≤10

Missing
Age at Menopause, N(%)

0.001

Author Manuscript

≤42

72 (14.5)

541 (19.1)

43-48

106 (21.3)

629 (22.2)

49-51

133 (26.8)

616 (21.8)

≥52

142 (28.6)

675 (23.9)

Missing

44 (8.8)

369 (13.0)

Parity, N(%)

0.04

0

79 (15.9)

334 (11.8)

1

39 (7.8)

254 (9.0)

375 (75.5)

2223 (78.6)

4 (0.8)

19 (0.6)

Yes

138 (27.8)

440 (15.5)

No

185 (37.2)

2164 (76.5)

Missing

174 (35.0)

226 (8.0)

Never

254 (51.1)

1519 (53.7)

Former

213 (42,9)

1021 (36.1)

Current

22 (4.4)

250 (8.8)

8 (1.6)

40 (1.4)

≥2
Missing
Family history of breast cancer, (N%),

<.0001
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Smoking status, N (%)

Missing

<.0001

0.001
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Cases (N=497)

Subcohort (N=2,830)
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Education history, N (%)

<.0001

High school and less

144 (29.0)

1125 (39.8)

College

203 (40.8)

982 (34.7)

Postgraduate education

143 (28.8)

701 (24.8)

7 (1.4)

22 (0.7)

Missing
Alcohol (servings per week)
Physical activity (METs‡)

P-value¶

0.4 (0.0 to 3.5)

0.2 (0.0 to 1.4)

<.0001

8.29 (2.00 to 17.50)

5.75 (0.50 to 15.00)

<.0001

P-values derived from Wilcoxon rank sum test for continuous data and Pearson’s chi-square for categorical data.
‡

MET, metabolic equivalent tasks (defined as the caloric need per kilogram of body weight per hour of activity divided by the caloric need per
kilogram of body weight per hour at rest) per hour per week.
§

Values are medians (inter-quartile range) unless otherwise stated.

Author Manuscript
Author Manuscript
Author Manuscript
Cancer Res. Author manuscript; available in PMC 2016 January 15.

Author Manuscript

Author Manuscript

Author Manuscript

Cancer Res. Author manuscript; available in PMC 2016 January 15.
175/1250

Metabolically Unhealthy4

HOMA-IR (quartile 1);

86/329

Metabolically Healthy3

Overweight (≥25

19/180

Kg/M2)

Metabolically Unhealthy4

Insulin (quartile 1);

1.86 (1.30-2.66)

0.93 (0.64-1.35)

1.86 (0.95-3.65)

1.00 (Referent)

Age-adjusted HR (95% CI)

1.60 (1.12-2.28)

0.93 (0.64-1.34)

1.68 (0.85-3.33)

1.00 (Referent)

Age-adjusted HR (95% CI)

0.001

0.71

0.07

P-Value

0.01

0.68

0.13

P-Value

2.01 (1.35-2.99)

0.96 (0.64-1.42)

2.06 (1.01-4.22)

1.00 (Referent)

Multivariate HR (95% CI)

1.76 (1.19-2.60)

0.96 (0.64-1.42)

1.80 (0.88-3.70)

1.00 (Referent)

Multivariate HR† (95% CI)

0.001

0.82

0.048

P-Value

0.005

0.83

0.11

P-Value

Insulin (quartiles 3+4); Adjusted for age, ethnicity, age at menarche and menopause, parity, first degree relative with breast cancer, education, alcohol consumption, physical activity, which of the two
WHI studies each subject was enrolled in and, among those who participated in the clinical trials, which specific clinical trial arm they were assigned to and whether they were a member of the placebo or
treatment group.

4

N (Cases/Controls)

108/352

(<25Kg/M2)

Metabolically Healthy3

Normal Weight

BMI Category

HOMA-IR (quartiles 3+4);

3

2

1

169/1238

Metabolically Unhealthy2

Insulin based definition of Metabolic Health

87/339

18/182

113/356

N (Cases/Controls)

Metabolically Healthy1

Overweight (≥25

Kg/M2)

Metabolically Unhealthy2

Metabolically Healthy1

Normal Weight (<25Kg/M2)

BMI Category

HOMA-IR based definition of Metabolic Health

The Associations of Incident Postmenopausal Breast Cancer Risk with Metabolic Health Defined by HOMA-IR or Insulin Levels, Stratified by Body
Mass Index (BMI) Category
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